Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New RNA Research Kits Save Time, Reduce Variability

By LabMedica International staff writers
Posted on 03 Jun 2010
Two assay kits for RNA research are among several new products recently made available to molecular biologists and genome researchers.

Two assay systems recently released for marketing by Qiagen (Hilden, Germany) focus on RNA research. More...
The first is called "FlexiTube siRNA Premix.” In this product siRNA for the gene of interest and a highly efficient transfection reagent are already premixed and provided in a single tube.

FlexiTube siRNA Premix includes a specialized buffer that increases the stability of siRNA-reagent complexes. The ratio of reagent to siRNA in FlexiTube siRNA Premix is preoptimized to provide the highest transfection efficiency and gene knockdown. FlexiTube siRNA Premix is ready-to-use for cell transfection. The user simply adds the reagents to cells and incubates. This saves a significant amount of time and labor compared to a typical transfection experiment in which siRNA is diluted, mixed with transfection reagent, and then incubated to allow siRNA-reagent complex formation prior to adding the complexes to the cells and incubating.

With FlexiTube siRNA Premix, RNAi experiments get off to a faster start, as there is no need to optimize siRNA to reagent ratio. Tedious optimization experiments involving multiple transfections are minimized or eliminated, as FlexiTube siRNA Premix provides siRNA and reagent premixed at an optimal ratio. Multiple transfections can be performed from a single FlexiTube siRNA Premix, which reduces variability, enabling consistency across experiments and more reliable results.

The second line of products for RNA research is "miScript Target Protectors.” These are innovative tools that provide valuable insights into the roles of miRNAs in regulation of individual genes. A miScript Target Protector is designed to protect the miRNA-binding site of a specific target gene. After transfection, the miScript Target Protector binds to the miRNA-binding site, blocking miRNA access to the site and preventing gene downregulation by a specific miRNA.

miScript Target Protector transfection is followed by phenotype or gene expression analysis. Increased target-gene expression, a change in signaling patterns, or an altered phenotype, can all provide evidence that the miRNA and target under study are involved in the pathway or phenotype of interest. The role of miRNAs in various pathways can be studied by examination of specific phenotypes after transfection of different miScript Target Protectors.

Information about these and other genomic research tools is easily accessed through the "GeneGlobe” portal located at Qiagen's website.

Related Links:
Qiagen



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.